On defining the rules for interactions between the T cell receptor and its ligand:: A critical role for a specific amino acid residue of the T cell receptor β chain

被引:39
作者
Wang, FM
Ono, T
Kalergis, AM
Zhang, WJ
DiLorenzo, TP
Lim, K
Nathenson, SG
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
[2] Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA
[3] Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA
关键词
D O I
10.1073/pnas.95.9.5217
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The specificity of T cell-mediated immune responses is primarily determined by the interaction between the T cell receptor (TCR) and the antigenic peptide presented by the major histocompatibility complex (MHC) molecules, To refine our understanding of interactions between the TCR and the antigenic peptide of vesicular stomatitis virus (VSV) presented by the class I MHC molecule H-2K(b), rye constructed a TCR alpha chain transgenic mouse in a TCR alpha-deficient background to define specific structural features in the TCR beta chain that are important for the recognition of the VSV/H-2K(b) complex. We found that for a given peptide, a peptide-specific, highly conserved amino acid could always be identified at position 98 of the complementarity-determining region 3 (CDR3) loop of TCR beta chains, Further, we demonstrated that substitutions at position 6, but not position 1, of the VSV peptide induced compensatory changes in the TCR in both the amino acid residue at position 98 and the length of the CDR3 beta loop. We conclude that the amino acid residue at position 98 of the CDR3 beta loop is a key residue that plays a critical role in determining the specificity of TCR-VSV/H-2K(b) interactions and that a specific length of the CDR3 beta loop is required to facilitate such interactions. Further, these findings suggest that the alpha and beta chains of TCRs interact with amino acid residue(s) toward the N and C termini of the VSV peptide, respectively, providing functional evidence for the orientation of a TCR with its peptide/MHC ligand as observed in the crystal structures of TCR/peptide/MHC complexes.
引用
收藏
页码:5217 / 5222
页数:6
相关论文
共 32 条
[1]   EXPRESSION OF T-CELL RECEPTOR ALPHA-CHAIN GENES IN TRANSGENIC MICE [J].
BERG, LJ ;
FAZEKAS DE ST GROTH, B ;
IVARS, F ;
GOODNOW, CC ;
GILFILLAN, S ;
GARCHON, HJ ;
DAVIS, MM .
MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (12) :5459-5469
[2]   T-CELL-SPECIFIC DELETION OF T-CELL RECEPTOR TRANSGENES ALLOWS FUNCTIONAL REARRANGEMENT OF ENDOGENOUS ALPHA-GENES AND BETA-GENES [J].
BLUTHMANN, H ;
KISIELOW, P ;
UEMATSU, Y ;
MALISSEN, M ;
KRIMPENFORT, P ;
BERNS, A ;
VONBOEHMER, H ;
STEINMETZ, M .
NATURE, 1988, 334 (6178) :156-159
[3]   EXCLUSION AND INCLUSION OF ALPHA-T-CELL AND BETA-T-CELL RECEPTOR ALLELES [J].
BORGULYA, P ;
KISHI, H ;
UEMATSU, Y ;
VONBOEHMER, H .
CELL, 1992, 69 (03) :529-537
[4]   ENGAGEMENT OF THE T-CELL RECEPTOR DURING POSITIVE SELECTION IN THE THYMUS DOWN-REGULATES RAG-1 EXPRESSION [J].
BRANDLE, D ;
MULLER, C ;
RULICKE, T ;
HENGARTNER, H ;
PIRCHER, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (20) :9529-9533
[5]   THE V-BETA-17+ T-CELL REPERTOIRE - SKEWED J-BETA USAGE AFTER THYMIC SELECTION - DISSIMILAR CDR3S IN CD4+ VERSUS CD8+ CELLS [J].
CANDEIAS, S ;
WALTZINGER, C ;
BENOIST, C ;
MATHIS, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (05) :989-1000
[6]   THE OUTLINE STRUCTURE OF THE T-CELL ALPHA-BETA-RECEPTOR [J].
CHOTHIA, C ;
BOSWELL, DR ;
LESK, AM .
EMBO JOURNAL, 1988, 7 (12) :3745-3755
[7]   IMPLICATIONS OF A FAB-LIKE STRUCTURE FOR THE T-CELL RECEPTOR [J].
CLAVERIE, JM ;
PROCHNICKACHALUFOUR, A ;
BOUGUELERET, L .
IMMUNOLOGY TODAY, 1989, 10 (01) :10-14
[8]  
DAVIS MM, 1990, ANNU REV BIOCHEM, V59, P475, DOI 10.1146/annurev.bi.59.070190.002355
[9]   T-CELL ANTIGEN RECEPTOR GENES AND T-CELL RECOGNITION [J].
DAVIS, MM ;
BJORKMAN, PJ .
NATURE, 1988, 334 (6181) :395-402
[10]  
ENGELHARD VH, 1994, ANNU REV IMMUNOL, V12, P181, DOI 10.1146/annurev.immunol.12.1.181